glp 1 pediatric obesity Role of GLP-1 Receptor Agonists in Obesity: Benefits, Risks, and Approaches to Patient Selection | Current Reports GLP-1s for Childhood Obesity: Ready

Only 40% of 2023 initiators remained on therapy after a year compared to 34% of 2022 initiators and 33% of 2021 initiators

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.

adults have obesity, with the rate increasing more than 10 percentage points in the past 2 decades

In the meantime.we in the Sarasohn-Kahn family wish you and your loved ones a healthy, joyful, peaceful and loving holiday season and 2026.JSK

Tirzepatide), metabolic outcomes, and next-gen weight loss benefits

Ideal for post-GLP-1 transitions and ongoing weight maintenance